Business
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
Calgary, Alberta--(Newsfile Corp. - July 31, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix",...
About this update from Resverlogix Corp.
[{"type":"text","content":"\nResverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture ExtensionCalgary, Alberta--(Newsfile Corp. - July 31, 2024) - Resverlogix Corp. (TSX: RVX) (\"Resverlogix\", or the \"Corporation\") today held its Annual & Special Meeting of Shareholders (the \"Meeting\") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected four (4) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:Votes ForVotes WithheldPercent ForPercent WithheldDonald J. McCaffrey131,554,9316,759,49895.11%4.89%Kelly McNeill132,370,4855,943,94495.70%4.30%Siu Lun (Dicky) To132,663,5935,650,83695.91%4.09%Kenneth Zuerblis132,354,2995,960,13095.69%4.31% Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated June 14, 2024 (the \"Information Circular\"). The Information Circular is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.A webcast archive of the executive presentation portion of the Meeting will be available HERE.Resverlogix also announced that it has closed the previously-announced two year extension of its US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd.About ResverlogixFounded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canad...